Bellerophon Therapeutics Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Craig Jalbert

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	no data
Board average tenure	no data

Recent management updates

Recent updates

CEO

Craig Jalbert (62 yo)

less than a year

Tenure

Mr. Craig R. Jalbert is President, Treasurer, CS, Principal Executive Officer, Financial Officer, & Principal Accounting Officer of NexImmune, Inc. from August 27, 2024 He is Chief Executive Officer, Presi...

Bellerophon Therapeutics Management

Management criteria checks 0/4

Key information

Recent management updates

Bellerophon Therapeutics, Inc. Announces Executive Changes

Bellerophon Therapeutics, Inc. Announces Resignation of Theodore Wang as a Member of the Company's Board

Insufficient new directors

Bellerophon Therapeutics, Inc. Announces Resignation of Crispin Teufel as Board of Director

Insider recently sold US$82k worth of stock

Insufficient new directors

Recent updates

Bellerophon Therapeutics, Inc. Files Form 15

Bellerophon Therapeutics, Inc. Announces Executive Changes

Nasdaq Determines to Delist the Bellerophon Therapeutics from Nasdaq Capital Market

Bellerophon Therapeutics, Inc. Announces Resignation of Theodore Wang as a Member of the Company's Board

Insufficient new directors

New major risk - Financial position

New major risk - Revenue and earnings growth

Bellerophon Therapeutics to Be Delisted from the Nasdaq Capital Market At Opening of Business on July 28, 2023 Unless It Timely Requests A Hearing Before Nasdaq Hearings Panel to Address Deficiencies and Present Plan to Regain Compliance

Bellerophon Therapeutics, Inc. Announces Resignation of Crispin Teufel as Board of Director

New major risk - Financial position

Bellerophon Therapeutics, Inc. Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

Insider recently sold US$82k worth of stock

Bellerophon Therapeutics, Inc. Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

Forecast to breakeven in 2025

Insufficient new directors

Bellerophon Therapeutics, Inc. Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse(R) in Fibrotic Interstitial Lung Disease

Bellerophon Therapeutics, Inc. Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

Insufficient new directors

Insufficient new directors

Bellerophon Provides Clinical Program Update

Insufficient new directors

Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 Rebuild Study of Inopulse for Treatment of Fibrotic Interstitial Lung Disease

Insufficient new directors

Insufficient new directors

Bellerophon Therapeutics, Inc. Announces New Board Appointment

Insufficient new directors

Bellerophon Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Insufficient new directors

Bellerophon Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Acute Dose Escalation Study of Inopulse® for Treatment of Pulmonary Hypertension Associated with Sarcoidosis

Bellerophon Therapeutics, Inc. Provides Clinical Program Update

Bellerophon Therapeutics, Inc.(NasdaqCM:BLPH) dropped from Russell 3000E Index

Chairman of the Board Jonathan Peacock has left the company

Bellerophon Therapeutics, Inc. Provides Clinical Program Update

Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease

Bellerophon Therapeutics, Inc. Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse for the Treatment of COVID-19

CEO

Tenure